Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific (NYSE: MLSS) announced a significant business update, reporting a 61% increase in Q1 2021 revenue to $2.9 million from $1.8 million year-over-year. Sequentially, sales rose 32% from Q4 2020. The company attributes this growth to a successful dental sales strategy and initial revenues from medical disposables, which they see as a transformative opportunity. Milestone’s innovative injection technology continues to position the company favorably in the biomedical market.
Milestone Scientific (MLSS) reported a 78% revenue increase in Q4 2020 compared to Q3, totaling approximately $1 million. Despite the impact of COVID-19, the company managed to reduce its net loss to approximately $(7.3) million or $(0.12 per share. Revenue for 2020 was $5.4 million, down from $8.3 million in 2019. The company is expanding its dental distribution network and has begun commercial efforts with the CompuFlo Epidural Instrument, focusing on high-margin disposable components and positive responses from hospitals. Cash reserves exceed $14 million.
Milestone Scientific Inc. (NYSE American: MLSS) announced a conference call scheduled for April 1, 2021, at 4:30 p.m. ET. The call will address the company's financial results for the year ending December 31, 2020, alongside updates on corporate progress and developments. U.S. callers can dial 1-877-407-0778, while international callers should use 201-689-8565. An audio replay will be accessible until April 15, 2021. The company specializes in computerized drug delivery systems aimed at making injections virtually painless. For further details, visit their website.
Milestone Scientific Inc. (NYSE: MLSS) announces that CEO Arjan Haverhals will present at the Q1 Virtual Investor Summit on March 24, 2021, at 11:00 AM ET. The summit will be held from March 23-25 and connects smallcap and microcap companies to investors. The event features 100 companies and over 300 investors. Milestone Scientific specializes in computerized drug delivery technologies, ensuring precise and virtually painless injections. For registration details, visit www.investorsummitgroup.com.
Milestone Scientific (NYSE American: MLSS) has received a Notice of Allowance from the European Patent Office for its innovative CompuFlo instrument, which combines minimum intensity of nerve stimulation and real-time injection pressure monitoring. This technology aims to improve ultrasound-guided peripheral nerve block (PNB) procedures by enhancing needle tip location and reducing injury risks. Developed in collaboration with experts, this advancement positions Milestone for growth in the PNB market, relevant for surgical and postoperative analgesia, with similar patent applications underway in the U.S.
Milestone Scientific (NYSE American:MLSS) has commenced the sale of its CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC), the top-ranked hospital in South Carolina. President Arjan Haverhals highlighted that this follows extensive testing by MUSC's team, reflecting a positive reception of the technologies. The CompuFlo system is noted to decrease epidural punctures and save time for anesthesiologists, while the CathCheck technology enhances catheter placement confirmation efficiency. These innovations may offer economic advantages for healthcare institutions.
Milestone Scientific Inc. (MLSS) announced a Notice of Allowance from the USPTO for its new CompuPulse System, which integrates the company's CompuWave™ technology with a manual syringe.
This development aims to enhance drug delivery safety and efficiency by verifying needle and catheter placement, thereby expanding the company's intellectual property and market reach. The CompuPulse System provides a cost-effective alternative for procedures that do not require advanced technology, while ensuring reliable confirmation during injections.
Milestone Scientific (NYSE:MLSS) announced its entry into the German market with the sale of the CompuFlo Epidural Instrument to the University Hospital of Würzburg. This agreement highlights the increasing recognition of the CompuFlo technology, which aims to enhance safety in epidural procedures by reducing accidental dural punctures. The company's leadership expressed optimism about expanding its global presence and accelerating commercialization efforts following this initial order from a prestigious European medical institution.
Milestone Scientific Inc. (MLSS) announced the expansion of its distributor network, signing agreements with Goetze Dental, Midwest Dental Equipment & Supply, and Scott's Dental in the U.S., along with Dental Fix Canada. This growth follows a rapid increase in partnerships, bringing the total to eight distributors in North America in less than a month. CEO Arjan Haverhals indicated that this strategy strengthens their position in the dental market, allowing for accelerated efforts in new global markets.
Milestone Scientific (NYSE: MLSS) announced its participation in the virtual Winter Wonderland Conference, hosted by The MicroCap Rodeo, from February 16th to 19th, 2021. The company’s Interim CEO Leonard Osser and President Jan Adriaan Haverhals will present on February 16th at 3:00 PM ET. The conference features top investment ideas and allows for one-on-one video meetings with qualified institutional investors. Milestone specializes in advanced injection technologies aimed at improving efficiency and patient comfort.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
